Craig-Hallum Maintains Buy on Repligen, Lowers Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Matt Hewitt maintains a Buy rating on Repligen (NASDAQ:RGEN) but lowers the price target from $207 to $200.

August 04, 2023 | 2:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Repligen's price target has been lowered from $207 to $200 by Craig-Hallum, though the Buy rating is maintained.
The news is directly related to Repligen and is likely to influence investor sentiment. While the lowered price target might be seen as a negative, the maintained Buy rating indicates that the analyst still sees potential in the stock. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100